BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 27485273)

  • 1. Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers.
    Notaro S; Reimer D; Fiegl H; Schmid G; Wiedemair A; Rössler J; Marth C; Zeimet AG
    BMC Cancer; 2016 Aug; 16():589. PubMed ID: 27485273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer.
    Schmid G; Notaro S; Reimer D; Abdel-Azim S; Duggan-Peer M; Holly J; Fiegl H; Rössler J; Wiedemair A; Concin N; Altevogt P; Marth C; Zeimet AG
    BMC Cancer; 2016 Feb; 16():102. PubMed ID: 26879132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
    Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
    Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA ploidy, nuclear size, proliferation index and DNA-hypomethylation in ovarian cancer.
    Zeimet AG; Fiegl H; Goebel G; Kopp F; Allasia C; Reimer D; Steppan I; Mueller-Holzner E; Ehrlich M; Marth C
    Gynecol Oncol; 2011 Apr; 121(1):24-31. PubMed ID: 21251700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.
    Köbel M; Madore J; Ramus SJ; Clarke BA; Pharoah PD; Deen S; Bowtell DD; Odunsi K; Menon U; Morrison C; Lele S; Bshara W; Sucheston L; Beckmann MW; Hein A; Thiel FC; Hartmann A; Wachter DL; Anglesio MS; Høgdall E; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Fogarty ZC; Vierkant RA; Liu S; Cho S; Nelson G; Ghatage P; Gentry-Maharaj A; Gayther SA; Benjamin E; Widschwendter M; Intermaggio MP; Rosen B; Bernardini MQ; Mackay H; Oza A; Shaw P; Jimenez-Linan M; Driver KE; Alsop J; Mack M; Koziak JM; Steed H; Ewanowich C; DeFazio A; Chenevix-Trench G; Fereday S; Gao B; Johnatty SE; George J; Galletta L; ; Goode EL; Kjær SK; Huntsman DG; Fasching PA; Moysich KB; Brenton JD; Kelemen LE
    Br J Cancer; 2014 Dec; 111(12):2297-307. PubMed ID: 25349970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic activation of POTE genes in ovarian cancer.
    Sharma A; Albahrani M; Zhang W; Kufel CN; James SR; Odunsi K; Klinkebiel D; Karpf AR
    Epigenetics; 2019 Feb; 14(2):185-197. PubMed ID: 30764732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of folate receptors alpha and beta in normal and cancerous gynecologic tissues: correlation of expression of the beta isoform with macrophage markers.
    O'Shannessy DJ; Somers EB; Wang LC; Wang H; Hsu R
    J Ovarian Res; 2015 May; 8():29. PubMed ID: 25971554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells.
    Huang MJ; Zhang W; Wang Q; Yang ZJ; Liao SB; Li L
    J Ovarian Res; 2018 Feb; 11(1):15. PubMed ID: 29433550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage.
    Woloszynska-Read A; Zhang W; Yu J; Link PA; Mhawech-Fauceglia P; Collamat G; Akers SN; Ostler KR; Godley LA; Odunsi K; Karpf AR
    Clin Cancer Res; 2011 Apr; 17(8):2170-80. PubMed ID: 21296871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LINE-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer.
    Pattamadilok J; Huapai N; Rattanatanyong P; Vasurattana A; Triratanachat S; Tresukosol D; Mutirangura A
    Int J Gynecol Cancer; 2008; 18(4):711-7. PubMed ID: 17944913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.
    Lee PS; Teaberry VS; Bland AE; Huang Z; Whitaker RS; Baba T; Fujii S; Secord AA; Berchuck A; Murphy SK
    Int J Cancer; 2010 Mar; 126(6):1378-89. PubMed ID: 19642140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients.
    Leung F; Dimitromanolakis A; Kobayashi H; Diamandis EP; Kulasingam V
    Clin Biochem; 2013 Oct; 46(15):1462-8. PubMed ID: 23528302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer.
    de Leon M; Cardenas H; Vieth E; Emerson R; Segar M; Liu Y; Nephew K; Matei D
    Gynecol Oncol; 2016 Sep; 142(3):539-47. PubMed ID: 27374141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PRAME expression and promoter hypomethylation in epithelial ovarian cancer.
    Zhang W; Barger CJ; Eng KH; Klinkebiel D; Link PA; Omilian A; Bshara W; Odunsi K; Karpf AR
    Oncotarget; 2016 Jul; 7(29):45352-45369. PubMed ID: 27322684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global hypomethylation is an independent prognostic factor in diffuse large B cell lymphoma.
    Wedge E; Hansen JW; Garde C; Asmar F; Tholstrup D; Kristensen SS; Munch-Petersen HD; Ralfkiaer E; Brown P; Grønbaek K; Kristensen LS
    Am J Hematol; 2017 Jul; 92(7):689-694. PubMed ID: 28378885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant Hypomethylation of Solute Carrier Family 6 Member 12 Promoter Induces Metastasis of Ovarian Cancer.
    Sung HY; Yang SD; Park AK; Ju W; Ahn JH
    Yonsei Med J; 2017 Jan; 58(1):27-34. PubMed ID: 27873492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer.
    Saito K; Kawakami K; Matsumoto I; Oda M; Watanabe G; Minamoto T
    Clin Cancer Res; 2010 Apr; 16(8):2418-26. PubMed ID: 20371677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HERV-K hypomethylation in ovarian clear cell carcinoma is associated with a poor prognosis and platinum resistance.
    Iramaneerat K; Rattanatunyong P; Khemapech N; Triratanachat S; Mutirangura A
    Int J Gynecol Cancer; 2011 Jan; 21(1):51-7. PubMed ID: 21330831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic regulation of folate receptor-α (FOLR1) in human placenta of preterm newborns.
    Piñuñuri R; Castaño-Moreno E; Llanos MN; Ronco AM
    Placenta; 2020 May; 94():20-25. PubMed ID: 32421530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA hypomethylation and ovarian cancer biology.
    Widschwendter M; Jiang G; Woods C; Müller HM; Fiegl H; Goebel G; Marth C; Müller-Holzner E; Zeimet AG; Laird PW; Ehrlich M
    Cancer Res; 2004 Jul; 64(13):4472-80. PubMed ID: 15231656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.